Ser242

Site Information
PGRRAsLsDLtDLED SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4149395

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:	breast cancer ( 2 ) , hepatocellular carcinoma, surrounding tissue ( 7 ) , lung cancer ( 1 , 4 , 6 ) , non-small cell lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	CL1-1 (pulmonary) ( 6 ) , CL1-2 (pulmonary) ( 6 ) , CL1-5 (pulmonary) ( 6 ) , H2009 (pulmonary) ( 4 ) , H2077 (pulmonary) ( 4 ) , H2887 (pulmonary) ( 4 ) , H322M (pulmonary) ( 4 ) , HCC1359 (pulmonary) ( 4 ) , HCC2279 (pulmonary) ( 4 ) , HCC366 (pulmonary) ( 4 ) , HCC4006 (pulmonary) ( 4 ) , HCC78 (pulmonary) ( 4 ) , hepatocyte-liver ( 7 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 2 ) , HMLER ('stem, breast cancer') ( 2 ) , HOP62 (pulmonary) ( 4 ) , Jurkat (T lymphocyte) ( 5 , 9 ) , leukocyte-blood ( 8 ) , liver ( 3 ) , NCI-H1395 (pulmonary) ( 4 ) , NCI-H1568 (pulmonary) ( 4 ) , NCI-H157 (pulmonary) ( 4 ) , NCI-H1666 (pulmonary) ( 4 ) , NCI-H2030 (pulmonary) ( 4 ) , NCI-H2172 (pulmonary) ( 4 ) , NCI-H322 (pulmonary) ( 4 ) , NCI-H647 (pulmonary) ( 4 ) , PC9 (pulmonary) ( 1 ) , TERT20 ('stem, mesenchymal') ( 10 )

Upstream Regulation
Treatments:	metastatic potential ( 6 )

References
1	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
2	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
3	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
4	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
5	Guo A (2011) CST Curation Set: 11849; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738 Curated Info
6	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
7	Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9 20166139 Curated Info
8	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
9	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
10	Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313 18578522 Curated Info